CODE :

NAME AND ADDRESS : ANIL DIGAMBAR GAWDE







Cert. No. MC-2010

SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

MAINDAI, 400002 MAHARASHTRA, INDIA Tel : 9111591115, Fax :				
			9PB1995PLC045956	
PATIENT NAME : ANIL DIGAMBAR GAW	/DE		PATIENT ID :	ANILM1106682
ACCESSION NO : 0002VK055355 AGE :	54 Years SEX : Male		ABHA NO :	
DRAWN : 26/11/2022 08:20:27 REC	EIVED : 26/11/2022 08:22:19		REPORTED : 29/11/2022	12:01:51
REFERRING DOCTOR : SELF			CLIENT PATIENT ID:	
Test Report Status <u>Final</u>	Results		Biological Reference In	terval Units
MEDI WHEEL FULL BODY HEALTH CHEC	K UP ABOVE 40 MALE			
BLOOD COUNTS,EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	14.4		13.0 - 17.0	g/dL
METHOD : PHOTOMETRIC MEASUREMENT				
RED BLOOD CELL (RBC) COUNT	5.07		4.5 - 5.5	mil/µL
METHOD : COULTER PRINCIPLE				
WHITE BLOOD CELL (WBC) COUNT	5.10		4.0 - 10.0	thou/µL
METHOD : COULTER PRINCIPLE				
PLATELET COUNT	270		150 - 410	thou/µL
METHOD : ELECTRONIC IMPEDENCE & MICROSCOPY				
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	44.0		40.0 - 50.0	%
METHOD : CALCULATED PARAMETER				
MEAN CORPUSCULAR VOLUME (MCV)	86.9		83.0 - 101.0	fL
METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM				
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	28.5		27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER				
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER	32.8		31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	13.9		11.6 - 14.0	%
METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM				
MENTZER INDEX	17.1			
MEAN PLATELET VOLUME (MPV)	7.2		6.8 - 10.9	fL
METHOD : DERIVED PARAMETER FROM PLATELET HISTOC	GRAM			
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	48		40 - 80	%
METHOD : VCSN TECHNOLOGY/ MICROSCOPY				
LYMPHOCYTES	35		20 - 40	%
METHOD : VCSN TECHNOLOGY/ MICROSCOPY				
MONOCYTES	8		2.0 - 10.0	%
METHOD : VCSN TECHNOLOGY/ MICROSCOPY				
EOSINOPHILS	8	High	1.0 - 6.0	%
METHOD : VCSN TECHNOLOGY/ MICROSCOPY				

1

0 - 1

METHOD : VCSN TECHNOLOGY/ MICROSCOPY

BASOPHILS



%

Scan to View Details



CODE :

NAME AND ADDRESS : ANIL DIGAMBAR GAWDE







Cert. No. MC-2010

SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956			
PATIENT NAME : ANIL DIGAMBAR GAWD	E	PATIENT ID : ANIL	M1106682
ACCESSION NO : 0002VK055355 AGE :	54 Years SEX : Male	ABHA NO :	
DRAWN : 26/11/2022 08:20:27 RECEIV	/ED: 26/11/2022 08:22:19	REPORTED : 29/11/2022 12:0	1:51
REFERRING DOCTOR : SELF		CLIENT PATIENT ID:	
Test Report Status <u>Final</u>	Results	Biological Reference Interva	al Units
ABSOLUTE NEUTROPHIL COUNT METHOD : CALCULATED PARAMETER	2.45	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT METHOD : CALCULATED PARAMETER	1.79	1.0 - 3.0	thou/µL
ABSOLUTE MONOCYTE COUNT METHOD : CALCULATED PARAMETER	0.41	0.2 - 1.0	thou/µL
ABSOLUTE EOSINOPHIL COUNT METHOD : CALCULATED PARAMETER	0.41	0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT METHOD : CALCULATED PARAMETER	0.05	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR) METHOD : CALCULATED	1.4		
ERYTHROCYTE SEDIMENTATION RATE (ES	SR),WHOLE		
E.S.R	9	0 - 14	mm at 1 hr
METHOD : AUTOMATED (PHOTOMETRICAL CAPILLARY STOPP	ED FLOW KINETIC ANALYSIS)		
GLYCOSYLATED HEMOGLOBIN(HBA1C), El BLOOD	DTA WHOLE		
HBA1C	5.3	Non-diabetic Adult < 5.7 Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
METHOD : ION- EXCHANGE HPLC			
ESTIMATED AVERAGE GLUCOSE(EAG)	105.4	< 116.0	mg/dL
METHOD : CALCULATED PARAMETER			
GLUCOSE FASTING, FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR)	87	Normal <100 Impaired fasting glucose:100 to 125 Diabetes mellitus: > = 126 (on more than 1 occassion) (ADA guidelines 2021)	

METHOD : SPECTROPHOTOMETRY HEXOKINASE

GLUCOSE, POST-PRANDIAL, PLASMA













SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

CODE : C000138400

NAME AND ADDRESS : ANIL DIGAMBAR GAWDE

	Tel		44, INDIA 1115, Fax : 9PB1995PLC045956	
PATIENT NAME : ANIL DIGAMBAR GAWD	E		PATIENT ID : ANIL	M1106682
ACCESSION NO : 0002VK055355 AGE :	54 Years SEX : Male		ABHA NO :	
DRAWN : 26/11/2022 08:20:27 RECEIV	/ED : 26/11/2022 08:22:1	19	REPORTED : 29/11/2022 12:0	01:51
REFERRING DOCTOR : SELF			CLIENT PATIENT ID:	
Test Report Status <u>Final</u>	Results		Biological Reference Interv	al Units
PPBS(POST PRANDIAL BLOOD SUGAR)	97		Normal <140 Impaired glucose tolerance:140 to 199 Diabetes mellitus : > = 200 (on more than 1 occassion) ADA guideline 2021	mg/dL
METHOD : SPECTROPHOTOMETRY HEXOKINASE LIPID PROFILE, SERUM			-	
CHOLESTEROL, TOTAL	179		Desirable : < 200 Borderline : 200 - 239 High : > / = 240	mg/dL
METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETR	IC - CHOLETSEROL OXIDASE, ESTE	RASE, PERC		
TRIGLYCERIDES	78		Normal: < 150 Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500	mg/dL
METHOD : SPECTROPHOTOMETRY, ENZYMATIC ENDPOINT W	ITH GLYCEROL BLANK		, , ,	
HDL CHOLESTEROL	56		At Risk: < 40 Desirable: > or = 60	mg/dL
METHOD : SPECTROPHOTOMETRY, HOMOGENEOUS DIRECT	ENZYMATIC COLORIMETRIC			
CHOLESTEROL LDL METHOD : CALCULATED PARAMETER	107	High	Optimal : < 100 Near optimal/above optimal : 129 Borderline high : 130-159 High : 160-189 Very high : = 190	mg/dL 100-
NON HDL CHOLESTEROL	123		Desirable : < 130	mg/dL
NON TIDE CHOLLSTEROL	125		Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220	ilig/uL
METHOD : CALCULATED PARAMETER				
CHOL/HDL RATIO	3.2	Low	Low Risk : 3.3 - 4.4 Average Risk : 4.5 - 7.0 Moderate Risk : 7.1 - 11.0 High Risk : > 11.0	
METHOD : CALCULATED PARAMETER				
LDL/HDL RATIO	2.0		Desirable/Low Risk : 0.5 - 3.0 Borderline/Moderate Risk : 3.1 6.0 High Risk : > 6.0	-
METHOD : CALCULATED PARAMETER			-	

METHOD : CALCULATED PARAMETER





CODE :

NAME AND ADDRESS : ANIL DIGAMBAR GAWDE







Cert. No. MC-2010

SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

PATTENT NAME : ANIL DIGAMBAR GAWDE PATTENT : ANILM1106682 ACCESSION NO: 0002VK055355 AGE: 54 Years SEX: Male ABHA NO: DRAWN: 26/11/2022 08:20:27 RECEIVED: 26/11/2022 08:22:19 REPORTED: 29/11/2022 12:01:51 REFERRING DOCTOR: SELF CLENT PATTENT ID: Test Report Status Enal Results Biological Reference Interval Units VERY LOW DENSITY LIPOPROTEIN 16.0 < or = 30.0 mg/dL METHOD: CAUGUATED PARAMETER BIOLINUMERTIC, COURTMENTIC-DUAZO METHOD Mg/dL BILIRUBIN, DIRECT 0.66 Upto 1.2 mg/dL METHOD: SPECTROPHOTOMETRY, UNDARASSILK & GROFT - 01A20TIZATION BILIRUBIN, DIRECT 0.40 0.1 - 1.0 mg/dL BILIRUBIN, DIRECT 0.40 0.1 - 1.0 mg/dL MethOD: SPECTROPHOTOMETRY, UNDARASSILK & GROFT - 01A20TIZATION g/dL BILIRUBIN, INDIRECT 0.40 0.1 - 1.0 mg/dL METHO: SPECTROPHOTOMETRY, UNDARASSILK & GROFT - 01A20TIZATION g/dL MethOD: SPECTROPHOTOMETRY, UNDARAMETRE g/dL ALBUMIN 2.6 0.0 - 3.5 g/dL MethOD: SPECTROPHOTOMETRY, UNDARAMETRE g/dL ALBUMIN/GLOBULIN RATIO 1.9 1.0 - 2.1 RATIO				01115, Fax : 09PB1995PLC045956	
DRAWN: 26/11/2022 08:20:27 RECEIVED: 26/11/2022 08:22:19 REPORTED: 29/11/2022 12:01:51 REFERRING DOCTOR: SELF CLIENT PATIENT ID: Test Report Status Einal Results Biological Reference Interval Units VERY LOW DENSITY LIPOPROTEIN 16.0 < or = 30.0 mg/dL METHOD: SALCUARDE PARAMETER BIURUBIN, TOTAL 0.66 Upto 1.2 mg/dL METHOD: SPECTROPHOTOMETRY, COLORIMETRY, COLOR	PATIENT NAME : ANIL DIGAMBAR GAW	DE		PATIENT ID:	ANILM1106682
REFERENCE DOCTOR: SELF CLIENT PATIENT LIPOPROTEIN Results Biological Reference Interval Units VERY LOW DENSITY LIPOPROTEIN 16.0 < or = 30.0 mg/dL METHOD: CalculateD PARAMETER mg/dL LIVE FUNCTION PROFILE, SERUE 0.66 Upto 1.2 mg/dL METHOD: SPECTROPHOTOMETRY, COLORIMETRIC: DIAZO METHOD 0.40 0.1 - 1.0 mg/dL METHOD: SPECTROPHOTOMETRY, COLORIMETRIC: DIAZO METHOD 0.40 0.1 - 1.0 mg/dL METHOD: SPECTROPHOTOMETRY, ENDRASSIK & GROFT - DIAZOTZATION 0.40 0.1 - 1.0 mg/dL METHOD: SPECTROPHOTOMETRY, ENDRASSIK & GROFT - DIAZOTZATION 0.40 0.1 - 1.0 mg/dL METHOD: SPECTROPHOTOMETRY, ENDRASSIK & GROFT - DIAZOTZATION 0.40 0.1 - 1.0 mg/dL METHOD: SPECTROPHOTOMETRY, RENDRASSIK & GROFT - DIAZOTZATION 0.40 0.1 - 1.0 Mg/dL METHOD: SPECTROPHOTOMETRY, RENDRASSIK & GROFT - DIAZOTZATION 0.40 0.40 0.40 METHOD: SPECTROPHOTOMETRY, RENDRASSIK & GROFT - DIAZOTZATION 0.40 0.40	ACCESSION NO : 0002VK055355 AGE :	54 Years SEX : Male		ABHA NO :	
Test Report Status Final Results Biological Reference Interval Units VERY LOW DENSITY LIPOPROTEIN METHOD: CALCULATED MAAMETER 16.0 < or = 30.0	DRAWN : 26/11/2022 08:20:27 RECE	IVED : 26/11/2022 08:22:19	9	REPORTED : 29/11/2	2022 12:01:51
VERY LOW DENSITY LIPOPROTEIN 16.0 < or = 30.0 mg/dL METHOD : CALCULATED PARAMETER ELIVER FUNCTION PROFILE, SERUM BILIRUBIN, TOTAL 0.66 Upto 1.2 mg/dL METHOD : SPECTROPHOTOMETRY, COLORIMETRIC - DIAZO METHOD BILIRUBIN, DIRECT 0.26 High 0.0 - 0.2 mg/dL METHOD : SPECTROPHOTOMETRY, DENDRASSIK & GROFF - DIAZOTIZATION BILIRUBIN, INDIRECT 0.40 0.1 - 1.0 mg/dL METHOD : SPECTROPHOTOMETRY, DENDRASSIK & GROFF - DIAZOTIZATION BILIRUBIN, INDIRECT 0.40 0.1 - 1.0 mg/dL METHOD : SPECTROPHOTOMETRY, COLORIMETRIC - BURET, REAGENT BLANK, SERUM BLANK ALBUMIN 7.5 6.0 - 8.0 g/dL METHOD : SPECTROPHOTOMETRY, COLORIMETRIC - BURET, REAGENT BLANK, SERUM BLANK ALBUMIN 2.6 2.0 - 3.5 g/dL METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCC) DVE BURDING GLOBULIN 2.6 2.0 - 3.5 g/dL METHOD : CALCULATED PARAMETER ALBUMIN/GLOBULIN RATIO 1.9 1.0 - 2.1 RATIO METHOD : CALCULATED PARAMETER ALBUMIN/GLOBULIN RATIO 1.9 1.0 - 2.1 RATIO METHOD : CALCULATED PARAMETER ALBUMIN/GLOBULIN RATIO 1.9 Upto 40 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC ALANINE AMINOTRANSFERASE (ALT/SGPT) 18 Upto 41 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC ALANINE AMINOTRANSFERASE (GGT) 10 < 60 U/L METHOD : SPECTROPHOTOMETRY, MUTHOUT PRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC LIACTATE DEHYDROGENASE 70 40 - 129 U/L METHOD : SPECTROPHOTOMETRY, MUTHOUT PRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC LIACTATE DEHYDROGENASE 157 < 232 U/L METHOD : SPECTROPHOTOMETRY, LACTATE TO PRIVATE - UV-IFCC BLOOD UREA NITROGEN 14 6 - 20 mg/dL METHOD : SPECTROPHOTOMETRY, LACTATE TO PRIVATE - UV-IFCC BLOOD UREA NITROGEN 14 6 - 20 mg/dL METHOD : SPECTROPHOTOMETRY, LACTATE TO PRIVATE - UV-IFCC BLOOD UREA NITROGEN 14 6 - 20 mg/dL METHOD : SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE KINETIC - ATTE BLANKED - IFCC-IDMS STANDARIZED	REFERRING DOCTOR : SELF			CLIENT PATIENT	ID :
METHOD : CALCULATED PARAMETER Utor 1.2 Method 1.2 BILLRUBIN, TOTAL 0.66 Upto 1.2 mg/dL METHOD : SPECTROPHOTOMETRY, COLORIMETRIC - DIAZO METHOD BILLRUBIN, DIRECT 0.26 High 0.0 - 0.2 mg/dL METHOD : SPECTROPHOTOMETRY, COLORIMETRIC - DIAZO METHOD BILLRUBIN, INDIRECT 0.40 0.1 - 1.0 mg/dL METHOD : SPECTROPHOTOMETRY, JENDRASSIK & GROFF - DIAZOTIZATION BILLRUBIN, INDIRECT 0.40 0.1 - 1.0 mg/dL METHOD : SECURATIONTOMETRY, JENDRASSIK & GROFF - DIAZOTIZATION BILLRUBIN, INDIRECT 0.40 0.1 - 1.0 mg/dL METHOD : SECURATIONTOMETRY, COLORIMETRIC - BIURET, REAGEMENT BLANK, SERUM BLANK JENDRASSIE g/dL METHOD : SECURATION TOMETRY, BROMOCRESOL GREEN(BCG) - DE BINDING g/dL METHOD : CALCULATED PARAMETER JENDRASSIE g/dL GLOBULIN 2.6 2.0 - 3.5 g/dL METHOD : CALCULATED PARAMETER JENDRASSIE JG/dL ALBUMIN/GLOBULIN RATIO 1.9 1.0 - 2.1 METHOD : CALCULATED PARAMETER JENDRASSIE JG/dL ALBUMIN/GLOBULIN RATIO 1.9 1.0 - 2.1 METHOD : CALCULATED PARAMETER JLANIK MINOTRANSFERASE (AST/SCOT)	Test Report Status <u>Final</u>	Results		Biological Reference	e Interval Units
LIVER FUNCTION PROFILE, SERUM 0.66 Upto 1.2 mg/dL BILRUSDIN, TOTAL 0.66 Upto 1.2 mg/dL METHOD : SPECTROPHIOTOMETRY, COLORIMETRIC - DIAZOTTZ-TON Mg/dL Mg/dL BILRUSDIN, INDIRECT 0.40 0.1 - 1.0 mg/dL METHOD : SPECTROPHIOTOMETRY, JENDRASSIK & GROFF - DIAZOTTZ-TON JG/d g/dL METHOD : CALCULATED PARAMETER 0.40 0.1 - 1.0 mg/dL METHOD : CALCULATED PARAMETER JG/d JG/d g/dL METHOD : SPECTROPHIOTOMETRY, COLORIMETRIC - BILRET, REAGENT BLANK, SERUM BLANK JS/7 - 4.94 g/dL METHOD : SPECTROPHIOTOMETRY, BROMOCRESOL GREEN(GS) - DYE BINDING JG/dL JG/dL JG/dL GLOBULIN 1.9 J.97 - 4.94 g/dL JG/dL METHOD : SPECTROPHIOTOMETRY, BROMOCRESOL GREEN(GS) - DYE BINDING JG/dL JG/dL JG/dL METHOD : SPECTROPHIOTOMETRY, UBROMOCRESOL GREEN(GS) - DYE BINDING JG/dL JG/dL JG/dL METHOD : SPECTROPHIOTOMETRY, UBROMOCRESOL GREEN(GS) 10 JG/D JG/dL JG/dL METHOD : SPECTROPHOTOMETRY, UBROMOCRESOL GREEN(GS) 10 JG/D JG/D JG/D JG/D JG/D <td< td=""><td></td><td>16.0</td><td></td><td>< or = 30.0</td><td>mg/dL</td></td<>		16.0		< or = 30.0	mg/dL
BLIRUBBIN, TOTAL 0.66 Upto 1.2 mg/dL METHOD: SPECTROPHIOTOMETRY, COLORIMETRIC - DIAZO METHOD Migh 0.0 - 0.2 mg/dL BULIRUBBIN, DIRECT 0.40 0.1 - 1.0 mg/dL METHOD: SECTROPHIOTOMETRY, JENDRASSIK & GROFF - DIAZO TZATON 0.40 0.1 - 1.0 mg/dL METHOD: CALCULATED PARAMETER 0.40 0.1 - 1.0 mg/dL METHOD: SPECTROPHIOTOMETRY, COLORIMETRIC - BIJURET, REAGENT BLANK, SERUM BLANK A.9 3.97 - 4.94 g/dL ALBUMIN 4.9 3.07 - 4.94 g/dL METHOD: SPECTROPHIOTOMETRY, BROMOCRESOL GREEN(BCG) - DYE BINDING G 0.0 - 2.1 RATIO METHOD: CALCULATED PARAMETER 1.9 1.0 - 2.1 RATIO METHOD: SPECTROPHIOTOMETRY, WITHOUT PRIDOXAL PROSPHATE ACTIVATION(PSP) - IFCC ALBUMIN/GLOBULIN RATIO 1.9 1.0 - 2.1 RATIO METHOD: SPECTROPHOTOMETRY, WITHOUT PRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC MICHOD: SPECTROPHOTOMETRY, WITHOUT PRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC ALANINE AMINOTRANSFERASE (ALT/SGPT) 18 Upto 41 U/L METHOD: SPECTROPHOTOMETRY, MERP, AMP BUFFER - IFCC ILACTATE DEHYDROBERMENT, MERP, AMP BUFFER - IFCC GAMMA GLUTAMYL TRANSFERASE (GGT) 10 60					
METHOD : SPECTROPHOTOMETRY, COLORIMETRIC - DIAZO METHOD BILLIRUBIN, DIRECT 0.26 High 0.0 - 0.2 mg/dL METHOD : SPECTROPHOTOMETRY JENDRASSIK & GROFF - DIAZOTIZATION BILLIRUBIN, INDIRECT 0.40 0.1 - 1.0 mg/dL METHOD : CALCULATED PARAMETER TOTAL PROTEIN 7.5 6.0 - 8.0 g/dL METHOD : SPECTROPHOTOMETRY, COLORIMETRIC - BULRET, REAGENT BLANK, SERUM BLANK ALBUMIN 4.9 3.97 - 4.94 g/dL METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - UP BINDING GLOBULIN 4.9 3.97 - 4.94 g/dL METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - UP BINDING GLOBULIN 4.9 1.9 1.0 - 2.1 RATIO METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - UP BINDING ALBUMIN/GLOBULIN RATIO 1.9 1.0 - 2.1 RATIO METHOD : CALCULATED PARAMETER ALBUMIN/GLOBULIN RATIO 1.9 UP to 40 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC ALANINE AMINOTRANSFERASE (ALT/SGPT) 1.8 UP to 41 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PHOLOXAL PHOSPHATE ACTIVATION(PSP) - IFCC ALKALINE PHOSPHATASE 70 40 - 129 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PHIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC ALKALINE PHOSPHATASE (ALT/SGPT) 1.0 < 60 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PHIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC ALKALINE PHOSPHATESE (ALT/SGPT) 1.0 < 2.32 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PHIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC ALKALINE PHOSPHATASE (GGT) 1.0 < 6.0 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PHIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC ALKALINE PHOSPHATESE (ALT/SGPT) 1.0 < 2.32 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PHIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC LACTATE DEHYDROGENASE (GGT) 1.0 < 2.32 U/L METHOD : SPECTROPHOTOMETRY, LACTATE TO PHILVATE - UV-IFCC BODD UREA NITROGEN [SUN], SERUM BLOOD UREA NITROGEN [SUN], SERUM CREAD [SUCTOPHOTOMETRY, UREASE - COLORIMETRIC - FATE BLANKED - IFCC-IDMS STANDARIZED CREATINE, SERUM		0.66			
BLIRUBIN, DIRECT 0.26 Mgh 0.0 - 0.2. mg/dL METHOD: SPECTROPHOTOMETRY, JENDRASSIK & GROFF - DIAZOTIZATION 3.40 0.1 - 1.0. mg/dL BLIRUBIN, INDIRECT 0.40 0.0 - 8.0. g/dL METHOD: CALCULATED PARAMETER 7.5 6.0 - 8.0. g/dL METHOD: SPECTROPHOTOMETRY, COLORIMETRIC - BUILET, REAGENT BLANK, SERUM BLANK 3.97 - 4.94 g/dL METHOD: SPECTROPHOTOMETRY, BROMOCRESCI GREEGES) OYE BINDING 2.0 - 3.5 g/dL GLOBULIN 2.6 2.0 - 3.5 g/dL METHOD: CALCULATED PARAMETER 1.9 1.0 - 2.1 RATIO METHOD: CALCULATED PARAMETER J J J ASPARTATE AMINOTRANSFERASE (AST/SGOT) 20 Upto 40 U/L METHOD: SPECTROPHOTOMETRY, WITHOUT PHRIDOXAL PHOSPHATE ACTIVATION (PSP) - IFCC J J J ALKANINE AMINOTRANSFERASE (ALT/SGFT) 18 Upto 41 U/L METHOD: SPECTROPHOTOMETRY, WITHOUT PHRIDOXAL PHOSPHATE ACTIVATION (PSP) - IFCC J J J ALKANINE PHOSPHATASE 10 < 60				Upto 1.2	mg/dL
METHOD : SPECTROPHOTOMETRY, JENDRASSIK & GROFF - DIAZOTIZATION BILIRUBIN, INDIRECT 0.400 0.1 - 1.0 mg/dL METHOD : CALCULATED PARAMETER TOTAL PROTEIN 7.5 6.0 - 8.0 g/dL METHOD : SPECTROPHOTOMETRY, COLORIMETRIC - BIURET, REAGENT BLANK, SERUM BLANK ALBUMIN 4.9 3.97 - 4.94 g/dL METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DYE BINDING GLOBULIN 2.6 2.0 - 3.5 g/dL METHOD : CALCULATED PARAMETER ALBUMIN/GLOBULIN RATIO 1.9 1.0 - 2.1 RATIO METHOD : CALCULATED PARAMETER ALBUMIN/GLOBULIN RATIO 1.9 Upto 40 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC ALANINO TRANSFERASE (AST/SGOT) 20 Upto 40 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC ALANINO TRANSFERASE (ALT/SGOT) 10 < 60 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC ALKALINE PHOSPHATASE 70 40 - 129 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC ALKALINE PHOSPHATASE (ALT/SGOT) 10 < 60 U/L METHOD : SPECTROPHOTOMETRY, RUPP, AMP BUFFER - IFCC GAMMA GLUTAMYL TRANSFERASE (GGT) 1 0 < 60 U/L METHOD : SPECTROPHOTOMETRY, RUPP, AMP BUFFER - IFCC LACTATE DEHYDOROGENASE 157 < 232 U/L METHOD : SPECTROPHOTOMETRY, RUPP, AMP BUFFER - IFCC BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN 14 6-20 mg/dL METHOD : SPECTROPHOTOMETRY, LACTATE TO PYRUVATE - UV-IFCC BLOOD UREA NITROGEN 14 6-20 mg/dL METHOD : SPECTROPHOTOMETRY, URASE -COLORIMETRIC - GLUTAMUL-CARBOXY-NITROANILIDE - IFCC CREATININE, SERUM CREATININE, SERUM BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN 0.14 6-20 mg/dL METHOD : SPECTROPHOTOMETRY, URASE -COLORIMETRIC CREATININE, SERUM CREATININE, SERUM CREATININE, SERUM			High	00-02	ma/dl
BLIRUBIN, INDIRECT 0.40 0.1 - 1.0 mg/dL METHOD : CALCULATED PARAMETER 7.5 6.0 - 8.0 g/dL TOTAL PROTEIN 7.9 6.0 - 8.0 g/dL METHOD : SPECTROPHOTOMETRY, COLORIMETRIC - BIURET, REAGENT LANK, SERUM BLANK 4.9 3.97 - 4.94 g/dL ALBUMIN 4.9 3.97 - 4.94 g/dL METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BC) - UT FUNDING g/dL g/dL METHOD : CALCULATED PARAMETER 1.0 - 2.1 RATIO ALBUMIN/GLOBULIN RATIO 1.9 1.0 - 2.1 RATIO METHOD : CALCULATED PARAMETER 1.9 Upto 40 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC Vanton 1.0 Vanton 1.0 ALANINE AMINOTRANSFERASE (ALT/SGOT) 1 Upto 41 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC Vanton 1.0 Vanton 1.0 METHOD : SPECTROPHOTOMETRY, UNPR, AMP BUFFER - IFCC U/L Vanton 1.0 Vanton 1.0 METHOD : SPECTROPHOTOMETRY, NUPP, AMP BUFFER - IFCC Vanton 2.32 U/L METHOD : SPECTROPHOTOMETRY, VENYMATIC COLORIMETRIC - G-ULT/MAU-CARBOXY-NITROANILIDE - IFCC Vanton 2.32 <t< td=""><td></td><td></td><td></td><td>0.0 0.2</td><td>ing/ac</td></t<>				0.0 0.2	ing/ac
METHOD: CALCULATED PARAMETER 7.5 6.0 - 8.0 g/dL TOTAL PROTEIN 7.5 6.0 - 8.0 g/dL METHOD: SPECTROPHOTOMETRY, COLORIMETRIC - BILNERT, REAGENT BLANK, SERUM BLANK 3.97 - 4.94 g/dL ALBUMIN 4.9 3.97 - 4.94 g/dL METHOD: SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - UP BINDING g/dL g/dL GLOBULIN 2.6 2.0 - 3.5 g/dL METHOD: CALCULATED PARAMETER . . . ALBUMIN/GLOBULIN RATIO 1.9 1.0 - 2.1 RATIO METHOD: SECTROPHOTOMETRY, WITHOUT PRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC . . ALANINE AMINOTRANSFERASE (AST/SGOT) 20 Upto 40 U/L METHOD: SPECTROPHOTOMETRY, WITHOUT PRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC . . ALANINE AMINOTRANSFERASE (ALT/SGPT) 18 Upto 41 U/L METHOD: SPECTROPHOTOMETRY, UNTHOUT PRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC . . GAMMA GLUTAMYL TRANSFERASE (GGT) 10 < 60				0.1 - 1.0	ma/dl
TOTAL PROTEIN 7.5 6.0 - 8.0 g/dL METHOD : SPECTROPHOTOMETRY, COLORIMETRIC - BJURET, REAGENT LLANK, SERUM BLANK 3.97 - 4.94 g/dL ALBUMIN 4.9 3.97 - 4.94 g/dL METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN (BCG) - DE BJUDING g/dL g/dL GLOBULIN 2.6 2.0 - 3.5 g/dL METHOD : CALCULATED PARAMETER J J.0 - 2.1 RATIO METHOD : CALCULATED PARAMETER J J.0 - 2.1 RATIO METHOD : CALCULATED PARAMETER J J.0 - 2.1 RATIO METHOD : CALCULATED PARAMETER J J.0 - 2.1 RATIO METHOD : SECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION (PSP) - IFCC J J.0 - 2.1 J.1 ALKALINE PHOSPHATASE 0 Upto 40 U/L J.1 METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION (PSP) - IFCC J.1 J.1 J.1 J.1 ALKALINE PHOSPHATASE 0 J.0 40 - 129 U/L J.1 METHOD : SPECTROPHOTOMETRY, NUPP, AMP BUFFER - IFCC J.1 S.2 J.2 J.1 GAMMA GLUTAMYL TRANSFERASE (GGT) 10 < 60	,	0.10		0.2 2.0	
METHOD: SPECTROPHOTOMETRY, COLORIMETRIC - BUNET, REAGENT BLANK, SERUM BLANK ALBUMIN 4.9 3.97 - 4.94 g/dL METHOD: SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DVE BUNDING J.0 2.0 - 3.5 g/dL GLOBULIN 2.6 2.0 - 3.5 g/dL METHOD: CALCULATED PARAMETER J.0 2.1 RATIO METHOD: CALCULATED PARAMETER J.9 1.0 - 2.1 RATIO METHOD: SPECTROPHOTOMETRY, WITHOUT PARIDOXAL PHOSPHATE ACTIVATION(P5P) - IFCC J.9 Upto 40 U/L METHOD: SPECTROPHOTOMETRY, WITHOUT PARIDOXAL PHOSPHATE ACTIVATION(P5P) - IFCC J.9 40 - 129 U/L METHOD: SPECTROPHOTOMETRY, WITHOUT PARIDOXAL PHOSPHATE ACTIVATION(P5P) - IFCC J.9 40 - 129 U/L METHOD: SPECTROPHOTOMETRY, WITHOUT PARIDOXAL PHOSPHATE ACTIVATION(P5P) - IFCC J.1 J.1 J.1 ALKALINE PHOSPHATASE 0 40 - 129 U/L J.1 METHOD: SPECTROPHOTOMETRY, NUTPHOUT PARIDOXAL PHOSPHATE ACTIVATIONAL PISO J.1		7.5		6.0 - 8.0	a/dL
ALBUMIN 4.9 3.97 - 4.94 g/dL METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - UF BINDING 2.6 2.0 - 3.5 g/dL GLOBULIN 2.6 2.0 - 3.5 g/dL METHOD : CALCULATED PARAMETER . RATIO METHOD : CALCULATED PARAMETER . RATIO METHOD : CALCULATED PARAMETER . NOT 2.1 ASPARTATE AMINOTRANSFERASE (AST/SGOT) 20 Upto 40 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PRIDOXAL PHOSPHATE ACTIVATION (PSP) - IFCC . U/L ALANINE AMINOTRANSFERASE (ALT/SGPT) 18 Upto 41 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PRIDOXAL PHOSPHATE ACTIVATION (PSP) - IFCC . U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PRIDOXAL PHOSPHATE ACTIVATION (PSP) - IFCC . U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PRIDOXAL PHOSPHATE ACTIVATION (PSP) - IFCC . U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PRIDOXAL PHOSPHATE ACTIVATION (PSP) - IFCC . U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PRIDOXAL PHOSPHATE ACTIVATION (PSP) - IFCC . U/L METHOD : SPECTROPHOTOMETRY, MARDERERSE (GGT) 10 < 60					5/ ==
METHOD: SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - VYE BINDING GLOBULIN 2.6 2.0 - 3.5 g/dL METHOD: CALCULATED PARAMETER Not an antipation of the second of				3.97 - 4.94	g/dL
METHOD : CALCULATED PARAMETER 1.9 1.0 - 2.1 RATIO METHOD : CALCULATED PARAMETER 0 Upto 40 U/L ASPARTATE AMINOTRANSFERASE (AST/SGOT) 20 Upto 40 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION (P5P) - IFCC U U/L ALANINE AMINOTRANSFERASE (ALT/SGPT) 18 Upto 41 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION (P5P) - IFCC U/L U/L ALKALINE PHOSPHATASE 70 40 - 129 U/L METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC U/L U/L METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC U/L U/L GAMMA GLUTAMYL TRANSFERASE (GGT) 10 < 60		(BCG) - DYE BINDING			5, -
METHOD : CALCULATED PARAMETER 1.9 1.0 - 2.1 RATIO METHOD : CALCULATED PARAMETER 0 Upto 40 U/L ASPARTATE AMINOTRANSFERASE (AST/SGOT) 20 Upto 40 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION (PSP) - IFCC Upto 41 U/L ALANINE AMINOTRANSFERASE (ALT/SGPT) 18 Upto 41 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION (PSP) - IFCC 40 - 129 U/L ALKALINE PHOSPHATASE 70 40 - 129 U/L METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC U/L GAMMA GLUTAMYL TRANSFERASE (GGT) 10 < 60	GLOBULIN	2.6		2.0 - 3.5	g/dL
METHOD : CALCULATED PARAMETER ASPARTATE AMINOTRANSFERASE (AST/SGOT) 20 Upto 40 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC ALANINE AMINOTRANSFERASE (ALT/SGPT) 18 Upto 41 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC ALKALINE PHOSPHATASE 70 40 - 129 U/L METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC GAMMA GLUTAMYL TRANSFERASE (GGT) 10 < 60 U/L METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - G-GLUTAMYL-CARBOXY-NITROANILIDE - IFCC LACTATE DEHYDROGENASE 157 <232 U/L METHOD : SPECTROPHOTOMETRY, LACTATE TO PYRUVATE - UV-IFCC BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN 14 6 - 20 mg/dL METHOD : SPECTROPHOTOMETRY, UREASE -COLORIMETRIC CREATININE, SERUM CREATININE, SERUM CREATININE 0.96 0.90 - 1.30 mg/dL	METHOD : CALCULATED PARAMETER				
ASPARTATE AMINOTRANSFERASE (AST/SGOT)20Upto 40U/LMETHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCCInto 40Upto 41U/LALANINE AMINOTRANSFERASE (ALT/SGPT)18Upto 41U/LMETHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCCInto 40 - 129U/LALKALINE PHOSPHATASE7040 - 129U/LMETHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCCInto 60U/LGAMMA GLUTAMYL TRANSFERASE (GGT)10< 60	ALBUMIN/GLOBULIN RATIO	1.9		1.0 - 2.1	RATIO
METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC Upto 41 U/L ALANINE AMINOTRANSFERASE (ALT/SGPT) 18 Upto 41 U/L METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC 40 - 129 U/L ALKALINE PHOSPHATASE 70 40 - 129 U/L METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC GAMMA GLUTAMYL TRANSFERASE (GGT) 10 < 60	METHOD : CALCULATED PARAMETER				
ALANINE AMINOTRANSFERASE (ALT/SGPT)18Upto 41U/LMETHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION (PSP) - IFCCA0 - 129U/LALKALINE PHOSPHATASE7040 - 129U/LMETHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCCSU/LGAMMA GLUTAMYL TRANSFERASE (GGT)10< 60	ASPARTATE AMINOTRANSFERASE (AST/SGOT	Г) 20		Upto 40	U/L
METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION(PSP) - IFCC V ALKALINE PHOSPHATASE 70 40 - 129 U/L METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC V V V GAMMA GLUTAMYL TRANSFERASE (GGT) 10 < 60	METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PI	HOSPHATE ACTIVATION(P5P) - IFCC			
ALKALINE PHOSPHATASE7040 - 129U/LMETHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCCGAMMA GLUTAMYL TRANSFERASE (GGT)10< 60	ALANINE AMINOTRANSFERASE (ALT/SGPT)	18		Upto 41	U/L
10< 60	METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PI	HOSPHATE ACTIVATION(P5P) - IFCC			
GAMMA GLUTAMYL TRANSFERASE (GGT)10< 60U/LMETHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - G-GLUTAMYL-CARBOXY-NITROANILIDE - IFCCLLLLACTATE DEHYDROGENASE157< 232	ALKALINE PHOSPHATASE	70		40 - 129	U/L
METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - G-ULTAMYL-CARBOXY-NITROANILIDE - IFCCIFCCLACTATE DEHYDROGENASE157< 232	METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFO	CC			
LACTATE DEHYDROGENASE 157 < 232	GAMMA GLUTAMYL TRANSFERASE (GGT)	10		< 60	U/L
METHOD : SPECTROPHOTOMETRY, LACTATE TO PYRUVATE - UV-IFCC BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN (BUN), SERUM METHOD : SPECTROPHOTOMETRY, UREASE -COLORIMETRIC CREATININE, SERUM CREATININE, SERUM CREATININE, SERUM O.96 0.90 - 1.30 mg/dL METHOD : SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE KINEKTER ELANKED - IFCC-IDMERTIZED	METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMET	ric - G-glutamyl-carboxy-nitroai	NILIDE - I	FCC	
BLOOD UREA NITROGEN (BUN), SERUM 14 6 - 20 mg/dL BLOOD UREA NITROGEN 14 6 - 20 mg/dL METHOD : SPECTROPHOTOMETRY, UREASE -COLORIMETRIC V V V CREATININE, SERUM 0.96 0.90 - 1.30 mg/dL METHOD : SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE KINKED - IFCC-IDM STALKALINE V Mg/dL	LACTATE DEHYDROGENASE	157		< 232	U/L
BLOOD UREA NITROGEN 14 6 - 20 mg/dL METHOD : SPECTROPHOTOMETRY, UREASE -COLORIMETRIC CREATININE, SERUM Mg/dL CREATININE, SERUM 0.96 0.90 - 1.30 mg/dL METHOD : SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE KINETIC- RATE BLANKED - IFCC-IDMSTRICE Mg/dL Mg/dL	METHOD : SPECTROPHOTOMETRY, LACTATE TO PYRUVATE -	- UV-IFCC			
METHOD : SPECTROPHOTOMETRY, UREASE -COLORIMETRIC CREATININE, SERUM CREATININE 0.96 0.90 - 1.30 mg/dL METHOD : SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE KINETIC - RATE BLANKED - IFCC-IDMS STANDARIZED	BLOOD UREA NITROGEN (BUN), SERUM				
CREATININE, SERUM CREATININE 0.96 0.90 - 1.30 mg/dL METHOD : SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE KINETIC - RATE BLANKED - IFCC-IDMS STANDARIZED mg/dL	BLOOD UREA NITROGEN	14		6 - 20	mg/dL
CREATININE 0.96 0.90 - 1.30 mg/dL METHOD : SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE KINETIC - RATE BLANKED - IFCC-IDMS STANDARIZED mg/dL	METHOD : SPECTROPHOTOMETRY, UREASE -COLORIMETRI	С			
METHOD : SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE KINETIC - RATE BLANKED - IFCC-IDMS STANDARIZED	CREATININE, SERUM				
	CREATININE	0.96		0.90 - 1.30	mg/dL
BUN/CREAT RATIO	METHOD : SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICR	ATE KINETIC - RATE BLANKED - IFCC-1	IDMS STA	NDARIZED	
	BUN/CREAT RATIO				

BUN/CREAT RATIO

8 - 15

14.60



Page 4 Of 19









SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA

NAME AND ADDRESS : ANIL DIGAMBAR GAWDE

	Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956		
PATIENT NAME : ANIL DIGAMBA			ANILM1106682
ACCESSION NO : 0002VK055355	AGE : 54 Years SEX : Male	ABHA NO :	
DRAWN : 26/11/2022 08:20:27	RECEIVED : 26/11/2022 08:22:19	REPORTED : 29/11/2022	2 12:01:51
REFERRING DOCTOR : SELF		CLIENT PATIENT ID:	
Test Report Status <u>Final</u>	Results	Biological Reference Ir	iterval Units
METHOD : CALCULATED PARAMETER			
URIC ACID, SERUM			
URIC ACID	3.4	3.4 - 7.0	mg/dL
METHOD : SPECTROPHOTOMETRY, ENZYMATIC	COLORIMETRIC- URICASE		
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.5	6.0 - 8.0	g/dL
METHOD : SPECTROPHOTOMETRY, COLORIMET	RIC -BIURET, REAGENT BLANK, SERUM BLANK		
ALBUMIN, SERUM			
ALBUMIN	4.9	3.97 - 4.94	g/dL
METHOD : SPECTROPHOTOMETRY, BROMOCRE	SOL GREEN(BCG) - DYE BINDING		
GLOBULIN			
GLOBULIN	2.6	2.0 - 3.5	g/dL
METHOD : CALCULATED PARAMETER			
ELECTROLYTES (NA/K/CL), SERU	М		
SODIUM, SERUM	142	136 - 145	mmol/L
METHOD : ISE INDIRECT			
POTASSIUM, SERUM	4.50	3.5 - 5.1	mmol/L
METHOD : ISE INDIRECT			
CHLORIDE, SERUM	103	98 - 106	mmol/L
METHOD : ISE INDIRECT			







NAME AND ADDRESS :

ANIL DIGAMBAR GAWDE







ANILM1106682

Cert. No. MC-2010

SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

PATIENT ID:

PATIENT NAME : ANIL DIGAMBAR GAWDE

C000138400

 ACCESSION NO:
 0002VK055355
 AGE:
 54 Years
 SEX:
 Male
 ABHA NO:

 DRAWN:
 26/11/2022 08:20:27
 RECEIVED:
 26/11/2022 08:22:19
 REPORTED:
 29/11/2022 12:01:51

 REFERRING DOCTOR:
 SELF
 CLIENT PATIENT ID:

Test	Report	Status	<u>Final</u>
------	--------	--------	--------------

Results

Biological Reference Interval Units

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion o extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative,corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

COLOR	PALE YELLOW	
APPEARANCE	CLEAR	
CHEMICAL EXAMINATION, URINE		
РН	6.0	5.00 - 7.50
SPECIFIC GRAVITY	1.025	1.010 - 1.030
PROTEIN	NOT DETECTED	NOT DETECTED
GLUCOSE	NOT DETECTED	NOT DETECTED
KETONES	NOT DETECTED	NOT DETECTED
BLOOD	NOT DETECTED	NOT DETECTED
BILIRUBIN	NOT DETECTED	NOT DETECTED
UROBILINOGEN	NOT DETECTED	
NITRITE	NOT DETECTED	NOT DETECTED







NAME AND ADDRESS :

ANIL DIGAMBAR GAWDE







ANILM1106682

Cert. No. MC-2010

SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

PATIENT ID:

CLIENT PATIENT ID:

29/11/2022 12:01:51

ABHA NO :

REPORTED :

PATIENT NAME : ANIL DIGAMBAR GAWDE

C000138400

ACCESSION NO : 0002VK055355 AGE : 54 Years SEX : Male

DRAWN : 26/11/2022 08:20:27 RECEIVED : 26/11/2022 08:22:19

REFERRING DOCTOR : SELF

Test Report Status <u>Final</u>	Results	Biological Reference I	interval Units
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	
MICROSCOPIC EXAMINATION, URINE			
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	1-2	0-5	/HPF
EPITHELIAL CELLS	0-1	0-5	/HPF
CASTS	NOT DETECTED		
CRYSTALS	NOT DETECTED		
BACTERIA	NOT DETECTED	NOT DETECTED	
YEAST	NOT DETECTED	NOT DETECTED	

METHOD : URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEGRATED AUTOMATED SYSTEM

Comments

NOTE: KINDLY EXERT CAUTION DURING INTERPRETATION OF FINDINGS REPORTED IN URINALYSIS WHERE IN THE SAMPLE IS MORE THAN TWO HOURS OLD.







CODE :

NAME AND ADDRESS : ANIL DIGAMBAR GAWDE







Cert. No. MC-2010

SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Test Report Status Final	Results	Biological Reference Interval Units
REFERRING DOCTOR : SELF		CLIENT PATIENT ID:
DRAWN : 26/11/2022 08:20:27	RECEIVED : 26/11/2022 08:22:19	REPORTED : 29/11/2022 12:01:51
ACCESSION NO : 0002VK055355	AGE : 54 Years SEX : Male	ABHA NO :
PATIENT NAME : ANIL DIGAMBA	AR GAWDE	PATIENT ID : ANILM1106682
	CIN - U74	4899PB1995PLC045956

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind
n na sen na se su se su	of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary
	tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by
	genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or
	bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration,
	interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl
	oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infection when present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis
HYROID PANEL, SERUM	vaginus, cervicius or saipingius

THYROID PANEL, SERUM

ТЗ	124.0	80.0 - 200.0	ng/dL
METHOD : COMPETITIVE ELECTROCHEMILUMINESCE	NCE IMMUNOASSAY		
T4	9.19	5.10 - 14.10	µg/dL
METHOD : COMPETITIVE ELECTROCHEMILUMINESCE	NCE IMMUNOASSAY		
TSH (ULTRASENSITIVE)	2.830	0.270 - 4.200	µIU/mL
METHOD : SANDWICH ELECTROCHEMILUMINESCEN	CE IMMUNOASSAY		





DIAGNOSTIC REPORT

C000138400







Cert. No. MC-2010

NAME AND ADDRESS :

CODE :

ANIL DIGAMBAR GAWDE

SRL Ltd
PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL
ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956

ACCESSION NO : 0002VK055355 AGE : 54 Years SEX : Male ABHA NO : DRAWN : 26/11/2022 08:20:27 RECEIVED : 26/11/2022 08:22:19 REPORTED : 29/11/2022 12:01:51 REFERRING DOCTOR : SELF CLIENT PATIENT ID :	nits
ACCESSION NO : 0002VK055355 AGE : 54 Years SEX : Male ABHA NO :	
PATIENT NAME : ANIL DIGAMBAR GAWDE PATIENT ID : ANILM110	6682

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

STOOL: OVA & PARASITE

COLOUR CONSISTENCY ODOUR BROWN SEMI FORMED FAECAL







NAME AND ADDRESS :

ANIL DIGAMBAR GAWDE







ANILM1106682

Cert. No. MC-2010

SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

ABHA NO :

REPORTED :

PATIENT ID:

29/11/2022 12:01:51

PATIENT NAME : ANIL DIGAMBAR GAWDE

C000138400

ACCESSION NO : 0002VK055355 AGE : 54 Years SEX : Male

DRAWN : 26/11/2022 08:20:27 RECEIVED : 26/11/2022 08:22:19

REFERRING DOCTOR : SELF

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units		
MUCUS	NOT DETECTED	NOT DETECTED		
VISIBLE BLOOD	ABSENT	ABSENT		
POLYMORPHONUCLEAR LEUKOCYTES	NOT DETECTED	0 - 5	/HPF	
METHOD : MICROSCOPIC EXAMINATION				
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF	
METHOD : MICROSCOPIC EXAMINATION				
MACROPHAGES	NOT DETECTED	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION				
CHARCOT-LEYDEN CRYSTALS	NOT DETECTED	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION				
TROPHOZOITES	NOT DETECTED	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION				
CYSTS	NOT DETECTED	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION				
OVA	NOT DETECTED			
METHOD : MICROSCOPIC EXAMINATION				
LARVAE	NOT DETECTED	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION				
ADULT PARASITE	NOT DETECTED			
METHOD : MICROSCOPIC EXAMINATION				
OCCULT BLOOD	NOT DETECTED	NOT DETECTED		
METHOD : MODIFIED GUAIAC METHOD				





CLIENT PATIENT ID:









C000138400 NAME AND ADDRESS :

ANIL DIGAMBAR GAWDE

CODE :

SRL Ltd
PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL
ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956

Test Report Status Final	Results	Biological Reference Interval Units
REFERRING DOCTOR : SELF		CLIENT PATIENT ID:
DRAWN : 26/11/2022 08:20:27	RECEIVED : 26/11/2022 08:22:19	REPORTED : 29/11/2022 12:01:51
ACCESSION NO : 0002VK055355	AGE: 54 Years SEX: Male	ABHA NO :
PATIENT NAME : ANIL DIGAMBA	AR GAWDE	PATIENT ID : ANILM1106682

Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION
Pus cells	Pus in the stool is an indication of infection
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis
Parasites Infection of the digestive system. Stool examination for ova and parasit presence of parasitic infestation of gastrointestinal tract. Various forms parasite that can be detected include cyst, trophozoite and larvae. One result does not rule out the possibility of parasitic infestation. Intermitted shedding of parasites warrants examinations of multiple specimens tests consecutive days. Stool specimens for parasitic examination should be or before initiation of antidiarrheal therapy or antiparasitic therapy. This to not detect presence of opportunistic parasites like Cyclospora, Cryptos and Isospora species. Examination of Ova and Parasite has been carried direct and concentration techniques.	
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.
Charcot-Leyden crystal	Parasitic diseases.
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.
Frank blood	Bleeding in the rectum or colon.
Occult blood	Occult blood indicates upper GI bleeding.
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.
рН	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.

ADDITIONAL STOOL TESTS:

- Stool Culture:- This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if 1. treatment for GI infection worked.
- 2. Fecal Calprotectin: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS).
- Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia. 3.
- Clostridium Difficile Toxin Assay: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to 4. overuse of broad spectrum antibiotics which alter the normal GI flora.
- 5. Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array Test, (Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus, parasite and other







CODE :

NAME AND ADDRESS :

ANIL DIGAMBAR GAWDE







Cert. No. MC-2010

SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Test Report Status Final	Results	Biological Reference Interval Units		
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :		
DRAWN : 26/11/2022 08:20:27	RECEIVED : 26/11/2022 08:22:19	REPORTED : 29/11/2022 12:01:51		
ACCESSION NO : 0002VK055355	AGE: 54 Years SEX: Male	ABHA NO :		
PATIENT NAME : ANIL DIGAMBAR GAWDE PATIENT ID : ANILM1106682				
	CIN - U/4	1899PB1995PLC045956		

opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.

6. <u>Rota Virus Immunoassay</u>: This test is recommended in severe gastroenteritis in infants & children associated with watery diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP	A	
METHOD : HAEMAGGLUTINATION (AUTOMATED)		
RH TYPE	POSITIVE	
METHOD : HAEMAGGLUTINATION (AUTOMATED)		
* XRAY-CHEST		
IMPRESSION	BILATERAL CERVICAL RIB	S NOTED.
TMT OR ECHO		
TMT OR ECHO	NEGATIVE	
* ECG		
ECG	SINUS ARRHYTHMIA OTHE	RIWISE NORMAL ECG
* MEDICAL HISTORY		
RELEVANT PRESENT HISTORY	RIGHT SHOULDER JOINT F OCC.BLEEDING PILES ACIDITY HEADACHE/EPIG.	
RELEVANT PAST HISTORY	NOT SIGNIFICANT	
RELEVANT PERSONAL HISTORY	NOT SIGNIFICANT	
RELEVANT FAMILY HISTORY	HYPERTENSION, CANCER	
HISTORY OF MEDICATIONS	NOT SIGNIFICANT	
* ANTHROPOMETRIC DATA & BMI		
HEIGHT IN METERS	1.68	mts
WEIGHT IN KGS.	57.4	Kgs
BMI	20	BMI & Weight Status as follows: kg/sqmts Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese
* GENERAL EXAMINATION		
MENTAL / EMOTIONAL STATE	NORMAL	
PHYSICAL ATTITUDE	NORMAL	
GENERAL APPEARANCE / NUTRITIONAL STATUS	HEALTHY	

AVERAGE



BUILT / SKELETAL FRAMEWORK











SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

CODE : C000138400

NAME AND ADDRESS : ANIL DIGAMBAR GAWDE

		1591115, Fax : 4899PB1995PLC045956	
PATIENT NAME : ANIL DIGAMBAR GAWDE		PATIENT ID : ANILM110	6682
ACCESSION NO : 0002VK055355 AGE : 54	Years SEX : Male	ABHA NO :	
DRAWN : 26/11/2022 08:20:27 RECEIVE	D: 26/11/2022 08:22:19	REPORTED : 29/11/2022 12:01:51	
REFERRING DOCTOR : SELF		CLIENT PATIENT ID:	
Test Report Status <u>Final</u>	Results	Biological Reference Interval U	nits
FACIAL APPEARANCE	NORMAL		
SKIN	NORMAL		
UPPER LIMB	NORMAL		
LOWER LIMB	NORMAL		
NECK	NORMAL		
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TEN	DER	
THYROID GLAND	NOT ENLARGED		
CAROTID PULSATION	NORMAL		
TEMPERATURE	NORMAL		
PULSE	72/MIN REGULAR, ALL I BRUIT	PERIPHERAL PULSES WELL FELT, NO CARO	οπρ
RESPIRATORY RATE	NORMAL		
* CARDIOVASCULAR SYSTEM			
BP	120/80 MM HG (SUPINE)	mm,	/Hg
PERICARDIUM	NORMAL		
APEX BEAT	NORMAL		
HEART SOUNDS	S1, S2 HEARD NORMAL	LY	
MURMURS	ABSENT		
* RESPIRATORY SYSTEM			
SIZE AND SHAPE OF CHEST	NORMAL		
MOVEMENTS OF CHEST	SYMMETRICAL		
BREATH SOUNDS INTENSITY	NORMAL		
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)		
ADDED SOUNDS	ABSENT		
* PER ABDOMEN			
APPEARANCE	NORMAL		
VENOUS PROMINENCE	ABSENT		
LIVER	NOT PALPABLE		
SPLEEN	NOT PALPABLE		
HERNIA	ABSENT		
* CENTRAL NERVOUS SYSTEM			
HIGHER FUNCTIONS	NORMAL		













SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

CODE : C000138400

NAME AND ADDRESS : ANIL DIGAMBAR GAWDE

	City 07	4899PB1995PLC0459		
PATIENT NAME : ANIL DIGAMBAR GAWDE		PAT	IENT ID:	ANILM1106682
ACCESSION NO : 0002VK055355 AGE : 54	Years SEX : Male	ABHA NO :		
DRAWN : 26/11/2022 08:20:27 RECEIVED	D: 26/11/2022 08:22:19	REPORTED :	29/11/20	22 12:01:51
REFERRING DOCTOR : SELF		CLIENT	PATIENT ID	:
Test Report Status <u>Final</u>	Results	Biological R	eference	Interval Units
CRANIAL NERVES	NORMAL			
CEREBELLAR FUNCTIONS	NORMAL			
SENSORY SYSTEM	NORMAL			
MOTOR SYSTEM	NORMAL			
REFLEXES	NORMAL			
* MUSCULOSKELETAL SYSTEM				
SPINE	NORMAL			
JOINTS	NORMAL			
* BASIC EYE EXAMINATION				
CONJUNCTIVA	NORMAL			
EYELIDS	NORMAL			
EYE MOVEMENTS	NORMAL			
CORNEA	NORMAL			
DISTANT VISION RIGHT EYE WITH GLASSES	WITH GLASSES NORMA	L (6/6)		
DISTANT VISION LEFT EYE WITH GLASSES	WITH GLASSES NORMA	L (6/6)		
NEAR VISION RIGHT EYE WITH GLASSES	WITHIN NORMAL LIMIT	(N6)		
NEAR VISION LEFT EYE WITH GLASSES	WITHIN NORMAL LIMIT	(N6)		
COLOUR VISION	NORMAL (17/17)			
* BASIC ENT EXAMINATION				
EXTERNAL EAR CANAL	NORMAL			
TYMPANIC MEMBRANE	NORMAL			
NOSE	NO ABNORMALITY DETE	CTED		
SINUSES	NORMAL			
THROAT	NO ABNORMALITY DETE	CTED		
TONSILS	NOT ENLARGED			
* BASIC DENTAL EXAMINATION				
TEETH	NORMAL			
GUMS	HEALTHY			
* SUMMARY				
RELEVANT HISTORY	NOT SIGNIFICANT			
RELEVANT GP EXAMINATION FINDINGS	NOT SIGNIFICANT			
RELEVANT LAB INVESTIGATIONS	RAISED EOSINOPHILS (RAISED LDL (107)	(8)		







NAME AND ADDRESS :

ANIL DIGAMBAR GAWDE







ANILM1106682

Cert. No. MC-2010

SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

PATIENT NAME : ANIL DIGAMBAR GAWDE

C000138400

ACCESSION NO : **0002VK055355** AGE : 54 Years SEX : Male ABHA NO : DRAWN : 26/11/2022 08:20:27 RECEIVED : 26/11/2022 08:22:19 REPORTED : 29/11/2022 12:01:51

CLIENT PATIENT ID:

PATIENT ID:

REFERRING DOCTOR : SELF

Test Report Status	<u>Final</u>	Results	Biological Reference Interval Units
RELEVANT NON PATHOL	OGY DIAGNOSTICS	USG-GRADE I PROS	TATOMEGALY

REMARKS / RECOMMENDATIONS

USG-GRADE I PROSTATOMEGALY MILD EOSINOPHILIA,RAISED LDL CHOLESTEROL REDUCE SATURATED FATS IN DIET ADV.PSA TEST FOLLOW UP WITH PHYSICIAN













NAME AND ADDRESS : ANIL DIGAMBAR GAWDE Cert. No. MC-2010

SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Test Report Status Final	Results	Units
REFERRING DOCTOR : SELF		CLIENT PATIENT ID:
DRAWN : 26/11/2022 08:20:27	RECEIVED : 26/11/2022 08:22:19	REPORTED : 29/11/2022 12:01:51
ACCESSION NO : 0002VK055355	AGE : 54 Years SEX : Male	ABHA NO :
PATIENT NAME : ANIL DIGAMBA	R GAWDE	PATIENT ID : ANILM1106682

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

*** ULTRASOUND ABDOMEN**

ULTRASOUND ABDOMEN

- GRADE I PROSTATOMEGALY (VOLUME ~ 30 CC).

- SUGGEST: PSA CORRELATION.

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait. WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope. ERYTHROCYTE SEDIMENTATION RATE (ESR),WHOLE BLOOD-**TEST DESCRIPTION** :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a same of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2.Diagnosing diabetes.

3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbAIc (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

2. AG gives an evaluation of blood glucose levels for the last couple of months.
 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

I.Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.



Page 16 Of 19 Scan to View Report

Scan to View Details



CODE :

NAME AND ADDRESS :

ANIL DIGAMBAR GAWDE







Cert. No. MC-2010

SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

PATIENT NAME : ANIL DIGAMBA	R GAWDE	PATIENT ID : ANILM1106682
ACCESSION NO : 0002VK055355	AGE : 54 Years SEX : Male	ABHA NO :
DRAWN : 26/11/2022 08:20:27	RECEIVED : 26/11/2022 08:22:19	REPORTED : 29/11/2022 12:01:51
REFERRING DOCTOR : SELF		CLIENT PATIENT ID:

Test Report Status Final Results Units	;
--	---

II.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results. IV.Interference of hemoglobinopathies in HbA1c estimation is seen in

a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.) c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides.

Decreased in

Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency, hypopituitarism,diffuse liver disease, malignancy (adrenocortical, stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol; sulfonylureas,tolbutamide, and other oral hypoglycemic agents.

NOTE:

Hypoglycemia is defined as a glucoseof < 50 mg/dL in men and < 40 mg/dL in women.

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemolytic anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis,sometimes due to a viral infection,ischemia to the liver,chronic hepatitis, obstruction of bile ducts, cirrhosis. ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction,

Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease,Rickets,Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia,Malnutrition,Protein deficiency,Wilson's disease.GGT is an enzyme found in cell membranes of many tissues mainly in the liver,kidney and pancreas.It is also found in other tissues including intestine,spleen,heart, brain and seminal vesicles.The highest concentration is in the kidney,but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease.Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc..Human serum albumin is the most abundant protein in human blood plasma.It is produced in the liver.Albumin constitutes about half of the blood serum protein.Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular

permeability or decreased lymphatic clearance, malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH. CREATININE, SERUM-Higher than normal level may be due to:

Blockage in the urinary tract

Kidney problems, such as kidney damage or failure, infection, or reduced blood flow

Loss of body fluid (dehydration)


Muscle problems, such as breakdown of muscle fibers

• Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:



Page 17 Of 19 äΞ 亡力 遷 Scan to View Report





CODE :

NAME AND ADDRESS :

ANIL DIGAMBAR GAWDE







Cert. No. MC-2010

SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

CLIENT PATIENT ID :

PATIENT NAME	: ANIL DIGAMBAR	R GAWDE		PA	TIENT ID :	ANILM1106682
ACCESSION NO :	0002VK055355	AGE: 54 Years	SEX : Male	ABHA NO :		
DRAWN : 26/11/2	2022 08:20:27	RECEIVED : 26/11,	/2022 08:22:19	REPORTED :	29/11/202	2 12:01:51

REFERRING DOCTOR : SELF

Test Report Status	<u>Final</u>	Results	Units
--------------------	--------------	---------	-------

Mvasthenia Gravis

Muscular dystrophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis TOTAL PROTEIN, SERUM-

Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum.. Protein in the plasma is made up of albumin and alobulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods. MEDICAL

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

End Of Report

Please visit www.srlworld.com for related Test Information for this accession TEST MARKED WITH '*' ARE OUTSIDE THE NABL ACCREDITED SCOPE OF THE LABORATORY.

Dr. J N Shukla ,MBBS, AFIH **Consultant Physician**



Dr. Ekta Patil, MD (Reg.No. MMC2008/04/1142) Senior Microbiologist

reen

8.wadal

Dr. Sushant Chikane **Consultant Pathologist**

Dr. Sneha Wadalkar.M.D (Reg.no.MMC2012/06/1868) Junior Biochemist







CODE :

NAME AND ADDRESS : ANIL DIGAMBAR GAWDE







Cert. No. MC-2010

SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Test Report Status Final	Results	Units
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :
DRAWN : 26/11/2022 08:20:27	RECEIVED : 26/11/2022 08:22:19	REPORTED : 29/11/2022 12:01:51
ACCESSION NO : 0002VK055355	AGE : 54 Years SEX : Male	ABHA NO :
PATIENT NAME : ANIL DIGAMBA	R GAWDE	PATIENT ID : ANILM1106682
		10551 D15551 EC045550

CONDITIONS OF LABORAT	ORY TESTING & REPORTING
 It is presumed that the test sample belongs to the patient named or identified in the test requisition form. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event. A requested test might not be performed if: Specimen received is insufficient or inappropriate Specimen quality is unsatisfactory Incorrect specimen type Discrepancy between identification on specimen container label and test requisition form 	 SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification. Test results cannot be used for Medico legal purposes. In case of queries please call customer care (91115 91115) within 48 hours of the report.
	SRL Limited Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



